Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension

References

• Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86–93.
   PubMed Web of Science ®Google Scholar
• Francis BA, Varma R, Chopra V, et al. Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino eye study. Am J Ophthalmol. 2008;146(5):741–746.
   PubMed Web of Science ®Google Scholar
• Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles Latino eye study. Ophthalmology. 2012;119(11):2245–2253.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medication or surgery. Ophthalmology. 2001;108(11):1943–1953.
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498–505.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911.
   PubMed Web of Science ®Google Scholar
• Goldberg I. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414–422.
   PubMed Web of Science ®Google Scholar
• O’Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomized study. Br J Ophthalmol. 2000;84(6):579–582.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Kulin NA, Tingey D, et al. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther. 2000;22(12):1502–1515.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.
   PubMed Web of Science ®Google Scholar
• Dasso L, Al-Khaled T, Sonty S, et al. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. 2018;12:1939–1944.
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688–703.
   PubMed Web of Science ®Google Scholar
• Kumar JB, Bosworth HB, Sleath B, et al. Quantifying glaucoma medication adherence: the relationship between self-report, electronic monitoring, and pharmacy refill. J Ocul Pharmacol Ther. 2016;32(6):346–354.
   PubMed Web of Science ®Google Scholar
• Wolfram C, Stahlberg E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharmacol Ther. 2019;35(4):223–228.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Blachley T, Lee PP, et al. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015;122(10):2010–2021.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Lee BW, Duncan M, et al. Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population. Arch Ophthalmol. 2011;129(7):872–878.
   PubMedGoogle Scholar
• Gray TA, Orton LC, Henson D, et al. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2019;15(2):CD0061312.
   Google Scholar
• Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009;50(11):5259–5265.
   PubMed Web of Science ®Google Scholar
• Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015;44–46:247–254.
   PubMed Web of Science ®Google Scholar
• Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci. 2006;47(3):953–963.
   PubMed Web of Science ®Google Scholar
• Anthony TL, Lindsey JD, Aihara M, et al. Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sclera. Invest Ophthalmol Vis Sci. 2001;42(13):3182–3186.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19(6):501–515.
   PubMed Web of Science ®Google Scholar
• Husain S, Jafri F, Crosson CE. Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. Invest Ophthalmol Vis Sci. 2005;46(5):1706–1713.
   PubMed Web of Science ®Google Scholar
• Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6–12.
   PubMed Web of Science ®Google Scholar
• Nakajima E, Nakajima T, Minagawa Y, et al. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci. 2005;94(4):201–708.
   Web of Science ®Google Scholar
• Tanna AP, Johnson M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology. 2018;125(11):1741–1756.
   PubMed Web of Science ®Google Scholar
• Loirand G. Rho kinases in health and disease: from basic science to translational research. Pharmacol Rev. 2015;67(4):1074–1095.
   PubMed Web of Science ®Google Scholar
• Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010;67(9):545–554.
   PubMed Web of Science ®Google Scholar
• Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs. 2007;21(3):167–177.
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):40–51.
   PubMed Web of Science ®Google Scholar
• Ren R, Li G, Le TD, et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197–6209.
   PubMed Web of Science ®Google Scholar
• Kazemi A, McLaren JW, Kopczynski CC, et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380–386.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Levy B, Ramirez N, et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100(3):339–344.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: 3-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248–257.
   PubMed Web of Science ®Google Scholar
• Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;204:97–104.
   Google Scholar
• The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440.
   PubMed Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2019;186:116–127.
   Web of Science ®Google Scholar